Balance and Gait Associations With Cognitive Impairment and Dementia in Individuals With Down Syndrome

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Citação
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, v.37, n.4, p.349-356, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Atypical aging in Down syndrome (DS) is associated with neuropathological characteristics consistent with Alzheimer disease. Gait abnormalities have been shown to be associated with an increased risk of dementia for the general population. The aim of this study was to determine whether gait disorders are associated with worse cognitive performance and dementia in adults with DS.Methods: We evaluated 66 individuals with DS (>= 20 y of age), divided into 3 groups: stable cognition, prodromal dementia, and dementia (presumed Alzheimer disease). Each individual was evaluated with the Performance-Oriented Mobility Assessment (POMA), Timed Up and Go test, and Cambridge Examination for Mental Disorders of Older People with Down's Syndrome and Others with Intellectual Disabilities (CAMDEX-DS), in addition to a comprehensive clinical protocol to ascertain the occurrence of medical or psychiatric comorbidities.Results: The score on the POMA-Gait subscale score and body mass index were found to be independent predictors of prodromal dementia and dementia (P<0.001 for both). With the exception of perception, all cognitive domains correlated with the POMA-Total score (P<0.05).Conclusion: A lower POMA-Gait score increases the chance of prodromal dementia and dementia in adults with DS. Unlike other research, in this study higher body mass index was also found to increase the chance of prodromal dementia and dementia. In those individuals, applying the POMA could facilitate the early diagnosis of dementia, help identify fall risks, and promote the adoption of geriatric interventions focused on improving functional mobility.
Palavras-chave
down syndrome, dementia, alzheimer disease, CAMDEX-DS, POMA, TUG, intellectual disability, gait
Referências
  1. Alhurani RE, 2016, JAMA NEUROL, V73, P439, DOI 10.1001/jamaneurol.2015.4756
  2. Anderson-Mooney AJ, 2016, BRAIN COGNITION, V104, P48, DOI 10.1016/j.bandc.2016.02.007
  3. Annus T, 2016, ALZHEIMERS DEMENT, V12, P538, DOI 10.1016/j.jalz.2015.07.490
  4. Association AP, 1994, DSM-IV, V4
  5. Ball SL, 2004, J INTELL DISABIL RES, V48, P611, DOI 10.1111/j.1365-2788.2004.00630.x
  6. Bayen E, 2018, JAMA NEUROL, V75, P1399, DOI 10.1001/jamaneurol.2018.2210
  7. Benejam B, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12047
  8. Bittles AH, 2007, EUR J PUBLIC HEALTH, V17, P221, DOI 10.1093/eurpub/ckl103
  9. Borges SD, 2018, AGING NEUROPSYCHOL C, V25, P23, DOI 10.1080/13825585.2016.1258035
  10. Borges SD, 2015, J MOTOR BEHAV, V47, P378, DOI 10.1080/00222895.2014.998331
  11. Borges SD, 2015, AGING NEUROPSYCHOL C, V22, P312, DOI 10.1080/13825585.2014.933770
  12. Buracchio T, 2010, ARCH NEUROL-CHICAGO, V67, P980, DOI 10.1001/archneurol.2010.159
  13. Cipriani G, 2018, AM J ALZHEIMERS DIS, V33, P253, DOI 10.1177/1533317518761093
  14. Cohen AD, 2018, ALZHEIMERS DEMENT, V14, P743, DOI 10.1016/j.jalz.2018.01.002
  15. Cosentino E, 2020, ALZ DIS ASSOC DIS, V34, P231, DOI 10.1097/WAD.0000000000000371
  16. Bottino CMD, 2012, ARQ NEURO-PSIQUIAT, V70, P165, DOI 10.1590/S0004-282X2012000300001
  17. Esbensen AJ, 2016, AJIDD-AM J INTELLECT, V121, P13, DOI 10.1352/1944-7558-121.1.13
  18. Fleming V, 2023, J ALZHEIMERS DIS, V91, P1215, DOI 10.3233/JAD-220865
  19. Fonseca LM, 2020, INT J GERIATR PSYCH, V35, P650, DOI 10.1002/gps.5283
  20. Fonseca LM, 2019, BRAZ J PSYCHIAT, V41, P225, DOI 10.1590/1516-4446-2018-0033
  21. Fortea J, 2020, LANCET, V395, P1988, DOI 10.1016/S0140-6736(20)30689-9
  22. Gomes GC., 2003, Traducao, adaptacao transcultural e exame das propriedades de medida da Escala ""Performance-oriented Mobility Assessment""(POMA) para uma amostragem de idosos brasileiros institucionalizados
  23. Goncalves AS., 2020, Alzheimers Dement, P16, DOI [10.1002/alz.047466, DOI 10.1002/ALZ.047466]
  24. Head E, 2016, CURR ALZHEIMER RES, V13, P18, DOI 10.2174/1567205012666151020114607
  25. Huang LK, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0609-7
  26. Hughes TF, 2020, EXP GERONTOL, V137, DOI 10.1016/j.exger.2020.110948
  27. Martínez-Espinosa RM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124294
  28. MATHIAS S, 1986, ARCH PHYS MED REHAB, V67, P387
  29. Niemann C, 2014, NEUROSCIENCE, V281, P147, DOI 10.1016/j.neuroscience.2014.09.033
  30. Organization WH, 1992, International Statistical Classification of Diseases and Related Health Problems, V3
  31. PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x
  32. Powell D, 2014, NEUROBIOL AGING, V35, P1562, DOI 10.1016/j.neurobiolaging.2014.01.137
  33. Prasher VP, 2004, RES DEV DISABIL, V25, P1, DOI 10.1016/j.ridd.2003.04.005
  34. RAZ N, 1995, NEUROLOGY, V45, P356, DOI 10.1212/WNL.45.2.356
  35. Rozalem Aranha M., 2023, Alzheimers Dement, V19, P1
  36. Smith E, 2011, OBES REV, V12, P740, DOI 10.1111/j.1467-789X.2011.00920.x
  37. Startin CM, 2019, ALZHEIMERS DEMENT, V15, P245, DOI 10.1016/j.jalz.2018.08.009
  38. TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5
  39. TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x
  40. Tsou AY, 2020, JAMA-J AM MED ASSOC, V324, P1543, DOI 10.1001/jama.2020.17024
  41. van Gijzen AFM, 2019, EUR J PEDIATR, V178, P559, DOI 10.1007/s00431-019-03322-x
  42. Van Pelt KL, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12092
  43. WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310
  44. Ylitalo KR, 2016, PREV MED, V91, P217, DOI 10.1016/j.ypmed.2016.08.044
  45. Zhang WH, 2019, DEMENT GERIATR COGN, V48, P17, DOI 10.1159/000504340
  46. Zigman WB, 2013, DEV DISABIL RES REV, V18, P51, DOI 10.1002/ddrr.1128